The latest price target for InflaRx (NASDAQ:IFRX) was reported by HC Wainwright & Co. on December 20, 2024. The analyst firm set a price target for $8.00 expecting IFRX to rise to within 12 months (a possible 257.14% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for InflaRx (NASDAQ:IFRX) was provided by HC Wainwright & Co., and InflaRx reiterated their buy rating.

The last upgrade for InflaRx NV happened on April 6, 2023 when Guggenheim raised their price target to N/A. Guggenheim previously had a neutral for InflaRx NV.

There is no last downgrade for InflaRx.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of InflaRx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for InflaRx was filed on December 20, 2024 so you should expect the next rating to be made available sometime around December 20, 2025.

While ratings are subjective and will change, the latest InflaRx (IFRX) rating was a reiterated with a price target of $8.00 to $8.00. The current price InflaRx (IFRX) is trading at is $2.24, which is out of the analyst’s predicted range.